ALKS vs ARWR: stock comparison and AI forecast
Alkermes Plc. (ALKS) and Arrowhead Pharmaceuticals, Inc. (ARWR) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ALKS Alkermes Plc.
- Price
- $45.69 +26.0% · 6M
- Market Cap
- $7.67B
- P/E Ratio
- 44.4x
- Size
- mid-cap
- AI Forecast
ARWR Arrowhead Pharmaceuticals, Inc.
- Price
- $60.49 -17.7% · 6M
- Market Cap
- $8.54B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- ARWR is 1.1 times larger than ALKS by market capitalization ($8.54B against $7.67B).
- Over the last six months ALKS returned +26.0% and ARWR -17.7%.
- ARWR carries 3.54 times debt per unit of equity, against 1.38 times for ALKS.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ALKS | ARWR |
|---|---|---|
| Market Cap | $7.67B | $8.54B |
| P/E Ratio | 44.36x | – |
| P/B Ratio | 4.11x | 18.35x |
| EPS | $1.03 | $-1.47 |
| Book Value/Share | $11.12 | $3.30 |
| Revenue/Share | $10.45 | $6.63 |
| FCF/Share | $1.36 | $-0.53 |
Profitability & Margins
| Metric | ALKS | ARWR |
|---|---|---|
| ROE | -0.0% | – |
| ROA | -0.0% | – |
| ROIC | 1.7% | -12.4% |
| Gross Margin | 82.9% | – |
| Operating Margin | 3.7% | -24.2% |
| Net Margin | -0.0% | – |
| EBT Margin | 0.7% | -26.9% |
| Tax Rate | 103.1% | -8.0% |
Financial Health
| Metric | ALKS | ARWR |
|---|---|---|
| Current Ratio | 2.42x | 5.90x |
| Quick Ratio | 2.02x | – |
| D/E Ratio | 1.38x | 3.54x |
| Financial Leverage | 2.38x | 4.54x |
| Interest Coverage | 14.7x | -2321.4x |
| Working Capital | $929M | $1.39B |
Cash Flow
| Metric | ALKS | ARWR |
|---|---|---|
| Operating Cash Flow | $243M | -$59M |
| Free Cash Flow | $227M | -$75M |
| Capital Spending | -$16M | -$16M |
| OCF Growth YoY | -55.1% | -370.3% |
| FCF Growth YoY | -53.7% | – |
| FCF/Sales | 13.0% | -8.0% |
| CapEx/Sales | 0.9% | 1.7% |
Operational Efficiency
| Metric | ALKS | ARWR |
|---|---|---|
| Asset Turnover | 0.40x | 0.44x |
| Receivables Turnover | 3.8x | 109.4x |
| Inventory Turnover | 1.1x | – |
| Fixed Assets Turnover | 8.2x | 2.5x |
| Days Sales Outstanding | 96 days | 3 days |
| Days Inventory | 318 days | – |
| Payables Period | 131 days | – |
| Cash Conversion Cycle | 282 days | – |
Income Statement
| Metric | ALKS | ARWR |
|---|---|---|
| Total Revenue | $1.75B | $936M |
| Operating Income | $64M | -$226M |
| Net Income | -$350K | – |
| R&D Expense | $430M | $723M |
| SG&A Expense | $878M | – |
| Cost of Goods Sold | $300M | – |
Dividend & Shareholder Information
| Metric | ALKS | ARWR |
|---|---|---|
| Shares Outstanding | 168M | 141M |
| Net Income Growth | -100.1% | – |
| EPS Growth | -51.2% | – |
ALKS vs ARWR: stock comparison and AI forecast
Which is bigger, ALKS or ARWR?
ARWR is 1.1 times larger than ALKS by market capitalization ($8.54B against $7.67B).
Which stock performed better over the last six months, ALKS or ARWR?
Over the last six months ALKS returned +26.0% and ARWR -17.7%.
Which one does Intratio's AI model rank higher, ALKS or ARWR?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.